Ratings by Wolfe Research (Rudy Li)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/7/2026 | Compass Pathways | CMPS | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Outperform (N/A) |
33.41 (31.41) |
-5.99% | Details | |
| 5/22/2026 | Alto Neuroscience | ANRO | New Coverage | Outperform (N/A) |
21.54 (27.54) |
27.86% | Details | |
| 5/22/2026 | Compass Pathways | CMPS | New Coverage | Outperform (N/A) |
11.59 (12.35) |
6.56% | Details | |
| 5/22/2026 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.30 (15.16) |
23.25% | Details | |
| 3/31/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Peerperform (Outperform) |
27.58 (40.50) |
46.85% | Details | |
| 2/24/2026 | uniQure BV | QURE | New Coverage | Peerperform (N/A) |
23.43 (40.25) |
71.79% | Details | |
| 2/24/2026 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
34.29 (29.05) |
-15.28% | Details | |
| 2/24/2026 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
42.23 (68.26) |
61.64% | Details | |
| 2/24/2026 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
183.72 (230.00) |
25.19% | Details | |
| 2/24/2026 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
128.63 (170.88) |
32.85% | Details | |
| 2/24/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
335.28 (314.41) |
-6.22% | Details | |
| 2/24/2026 | Acadia Pharmaceuticals | ACAD | New Coverage | Outperform (N/A) |
23.99 (25.60) |
6.71% | Details | |
| 2/24/2026 | Denali Therapeutics Inc. | DNLI | New Coverage | Peerperform (N/A) |
20.19 (23.29) |
15.35% | Details | |
| 2/24/2026 | Alkermes | ALKS | New Coverage | Outperform (N/A) |
31.91 (52.72) |
65.21% | Details | |
| 2/24/2026 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
24.50 (27.58) |
12.57% | Details | |
| 2/23/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Outperform (N/A) |
17.13 (44.29) |
158.55% | Details |
